Generic Drug Makers Launch Legal Challenge to New Federal Data Exclusivity Rules
14th Nov 2006, 16:56 GMT
TORONTO, Nov. 14 /CNW/ - Canada's generic pharmaceutical industry today launched legal action in the Federal Court of Canada challenging recent changes to federal regulations that provide brand-name drug...
Generic Drug Makers Launch Legal Challenge to New Federal Data Exclusivity Rules related news:
- Generic drug makers launch suit against federal patent rules — The Globe and Mail - Health News
- Generic-drug makers challenge new Canadian patent rules — CBC | Health News
- Court Backs Generic Drug Makers — WSJ.com: US Business
- Teva Says Generic Zocor Decision Upheld — Financial News News from StratCenter.com
- Teva, Ranbaxy exclusivity on generic Zocor confirmed — HomePage
- Beijing challenge on shoes — BBC News | Business | Economy | World Edition
- China backs legal move on shoes — BBC News | Asia-Pacific | World Edition
- T-Mobile Pearl exclusivity 'til December 1: how ironclad is this? — BBHub
- Beijing backs shoe challenge — BBC News | Business | UK Edition
- Beijing backs legal move on shoes — BBC News | Business | Economy | World Edition
Latest news from ArriveNet : Government:
- IAPP and (ISC)2 to Host Roundtable on Privacy, Security and the 110th U.S. Congress
- Mindready Solutions Reports Third Quarter 2006 Results
- Fuel Frontiers President Jack Young to Address the Future Fuels 2006 Conference in Washington, DC
- LynuxWorks and Communications Research Centre Join Forces to Deliver New Development Environment for Software Defined Radio Systems
- Reminder - Los Angeles World Airports Launches New Radio Station at Ontario International Airport to Provide Security and Travel Information
- Nano-Proprietary, Inc. Receives Contract for Biological and Chemical Air Purification System
- Municipalities' attack is "ill-advised" - School board association welcomes proposed relief for taxpayers
- Pension Advocacy Group Pleased with Government's Decision to Review Ontario Pension Legislation
- A Prescription for Healthcare Transformation: IBM Study Outlines Course of Action for a Sustainable Healthcare Industry
- Average Cost to Develop a New Biotechnology Product Is $1.2 Billion, According to the Tufts Center for the Study of Drug Development